Seller record · zappyhealth.com

Zappy Health

Recorded September 2026 · Standard v1.1

Fails 3 of 8 criteria. S3, pharmacy identification: Eight pages were read, covering the terms, help, contact, safety and treatment surfaces, and each states only that licensed pharmacies dispense the compounded medication. 2 more criteria also fail; see the table below.

Telehealth service. Passes 4 of 8 criteria. 1 not verified, counting neither way. Recorded against Standard v1.1.

A telehealth service selling compounded GLP-1 drugs beside NAD+, glutathione and sermorelin stacks. Its own pages name Zappy Health inc, the FDA letter addressed to this storefront names a different company, and the two are reconciled on no page read.

Operating entity Zappy Health inc

Dispositions

Code	Criterion	Disposition	Where it was read
S1	Prescriber requirement	PASS	zappyhealth.com
S2	Prescription gating	NOT VERIFIED	zappyhealth.com/start-now
S3	Pharmacy identification	FAIL	zappyhealth.com/contact
S4	Compounding disclosure	PASS	zappyhealth.com
S5	Analytical documentation	FAIL	zappyhealth.com/help
S6	Business address	FAIL	zappyhealth.com/contact
S7	Price disclosure	PASS	zappyhealth.com/contact
S8	Enforcement status	PASS	FDA warning-letter index

Evidence, criterion by criterion

What was read, where, and on what date, for each disposition in the table above.

S1PASSThe homepage states that treatment options are prescribed by licensed healthcare providers based on clinical evaluation, and it names no individual prescriber.Source: zappyhealth.com.

S2NOT VERIFIEDThe order path did not resolve, because the start, eligibility and booking pages each reset the connection on every attempt by two different methods, while the treatment pages loaded normally in the same session. The check is open.Source: zappyhealth.com/start-now.

S3FAILEight pages were read, covering the terms, help, contact, safety and treatment surfaces, and each states only that licensed pharmacies dispense the compounded medication.Source: zappyhealth.com/contact.

S4PASSThe homepage states that compounded drugs are not Food and Drug Administration approved and that the agency does not evaluate them for safety, effectiveness or quality.Source: zappyhealth.com.

S5FAILEight pages were searched for thirteen certificate and testing terms, and none returns a certificate, a lot number or a purity figure.Source: zappyhealth.com/help.

S6FAILEight pages were read, covering footer, contact, terms, help and the safety surfaces, and none prints a street address; the letter addressed to this storefront prints a La Jolla address the site itself does not publish.Source: zappyhealth.com/contact.

S7PASSThe treatment menu prints monthly figures with no account required, from 99 dollars per month for the weight-loss program and 119 dollars per month for two further programs.Source: zappyhealth.com/contact.

S8PASSFDA warning letter 717991, February 2026, names Kare Solutions, LLC doing business as Zappy and cites claims naming the compounded product as the same active ingredient as an approved brand. No FDA action has halted the business, and the seller still trades.Source: FDA warning-letter index.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, brand GLP-1 prescriptions, NAD+ injectable and spray, glutathione, sermorelin.

Enforcement documents on file: 1 warning letter

FDA warning letter 717991, issued February 2026, to Kare Solutions, LLC dba ZappyClaims on zappyhealth.com naming compounded products as the same active ingredient as approved brand drugs are false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.